Summary
A meta-analysis of 6 randomized trials demonstrated that when compared with aspirin therapy alone, dual antiplatelet therapy beyond 1 year decreased the risk of major adverse cardiovascular events, myocardial infarction, stroke, and cardiovascular death among high-risk patients with previous myocardial infarction while increasing the risk of major bleeding.
- DAPT
- dual antiplatelet therapy
- MACE
- major adverse cardiovascular event
- major bleeding
- MI
- myocardial infarction
- © 2015 SAGE Publications